Q4 2025 Cencora Inc Earnings Call Transcript

Nov 5, 2025 / 01:30 PM GMT

Release Date Price: €305.95 (+1.98%)

Transcript 8-K

Key Points

Positve

Cencora Inc (COR) reported a 16% growth in adjusted operating income and adjusted diluted EPS, driven by strategic investments and strong pharmaceutical utilization trends.
The company raised its long-term guidance for adjusted operating income growth to 6-9% and adjusted EPS growth to 9-13%, reflecting confidence in continued market growth.
Significant investments totaling $1 billion through 2030 are planned to enhance the distribution network, including a second national distribution center, to support customer growth and innovation.
The acquisition of Retina Consultants of America (RCA) has been successful, contributing positively to the company's specialty segment and enhancing its value proposition.
Cencora Inc (COR) announced a 9% increase in its quarterly dividend, marking the 21st consecutive annual dividend increase, aligning with its long-term EPS growth guidance.

Negative

The company is facing a $724 million goodwill impairment related to Pharmalex due to persistent demand challenges, leading to a strategic review and simplification of Pharmalex's business.
Net interest expense increased by $57 million, primarily due to debt raised for the RCA acquisition, impacting overall financial performance.
The loss of an oncology customer due to acquisition by a peer presents a headwind for the first three quarters of fiscal 2026.
International Healthcare Solutions segment saw a 2% decrease in operating income, primarily due to pressure in global consulting services businesses.
The company is exploring strategic alternatives for certain non-core businesses, which may lead to short-term dilution if these businesses are sold.

Refinitiv StreetEvents Event Transcript
P R E L I M I N A R Y V E R S I O N

COR.N - Cencora Inc
Q4 2025 Cencora Inc Earnings Call
Nov 05, 2025 / 01:30PM GMT

=====================
Conference Call Participants
=====================
* >>NOTE
* >>Transcription Start

=====================
Presentation
--------------------------------------------------------------------------------
>>NOTE [1]
--------------------------------------------------------------------------------

THIS TRANSCRIPT IS THE INITIAL PRELIMINARY VERSION WHICH LEVERAGES MACHINE LEARNING TECHNOLOGY. AS SUCH, PLEASE BE AWARE THERE MAY BE INACCURACIES IN THE TEXT DISPLAYED. FUTURE EDITED VERSIONS WILL BE REVIEWED FOR GREATER ACCURACY.

--------------------------------------------------------------------------------
>>Transcription Start, [2]
--------------------------------------------------------------------------------

Hello everyone, and thank you for joining the Sancora Fiscal

2025, 4th quarter and 4 year results call.

My name is Lucy, and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.